March 27, 2023
The Ministry of Health, Labor and Welfare (MHLW) on March 24 granted sakigake designation to two APIs - Chugai Pharmaceutical’s satralizumab and Lundbeck Japan’s Lu AF82422. Satralizumab snagged the status for two proposed indications, autoimmune encephalitis and myelin oligodendrocyte glycoprotein...read more